Journal article
Antibody-directed myostatin inhibition enhances muscle mass and function in tumor-bearing mice
KT Murphy, A Chee, BG Gleeson, T Naim, K Swiderski, R Koopman, GS Lynch
American Journal of Physiology Regulatory Integrative and Comparative Physiology | Published : 2011
Abstract
Cancer cachexia describes the progressive skeletal muscle wasting and weakness in many cancer patients and accounts for >20% of cancer-related deaths. We tested the hypothesis that antibody-directed myostatin inhibition would attenuate the atrophy and loss of function in muscles of tumor-bearing mice. Twelve-week-old C57BL/6 mice received a subcutaneous injection of saline (control) or Lewis lung carcinoma (LLC) tumor cells. One week later, mice received either once weekly injections of saline (control, n = 12; LLC, n = 9) or a mouse chimera of anti-human myostatin antibody (PF-354, 10 mg·kg -1·wk -1, LLC+PF-354, n = 11) for 5 wk. Injection of LLC cells reduced muscle mass and maximum force ..
View full abstractGrants
Awarded by National Health and Medical Research Council of Australia (NHMRC)
Funding Acknowledgements
This study was supported by research grants from Pfizer Global Research and Development (USA) and in part from the National Health and Medical Research Council of Australia (NHMRC) Project Grant 566820. K. T. Murphy is supported by a Biomedical Australian Fellowship from the National Health and Medical Research Council; R. Koopman is supported by a C.R. Roper Senior Research Fellowship from the Faculty of Medicine, Dentistry and Health Sciences at The University of Melbourne.